Impact of the obesity epidemic on hypertension and renal disease
- PMID: 12948431
- DOI: 10.1007/s11906-003-0084-z
Impact of the obesity epidemic on hypertension and renal disease
Abstract
Excess weight gain is a major cause of increased blood pressure in most patients with essential hypertension, and also greatly increases the risk for renal disease. Obesity raises blood pressure by increasing renal tubular reabsorption, impairing pressure natriuresis, causing volume expansion due to activation of the sympathetic nervous system and renin-angiotensin system, and by physical compression of the kidneys, especially when visceral obesity is present. The mechanisms of sympathetic nervous system activation in obesity may be due, in part, to hyperleptinemia that stimulates the hypothalamic pro-opiomelanocortin pathway. With prolonged obesity, there may be a gradual loss of nephron function that worsens with time and exacerbates hypertension. Weight reduction is an essential first step in the management of obesity hypertension and renal disease. Special considerations for the obese patient, in addition to adequately controlling the blood pressure, include correction of the metabolic abnormalities and protection of the kidneys from further injury.
Similar articles
-
Pathophysiology and treatment of obesity hypertension.Curr Pharm Des. 2004;10(29):3621-37. doi: 10.2174/1381612043382855. Curr Pharm Des. 2004. PMID: 15579059 Review.
-
Is obesity a major cause of chronic kidney disease?Adv Ren Replace Ther. 2004 Jan;11(1):41-54. doi: 10.1053/j.arrt.2003.10.007. Adv Ren Replace Ther. 2004. PMID: 14730537 Review.
-
Obesity-induced hypertension: interaction of neurohumoral and renal mechanisms.Circ Res. 2015 Mar 13;116(6):991-1006. doi: 10.1161/CIRCRESAHA.116.305697. Circ Res. 2015. PMID: 25767285 Free PMC article. Review.
-
Obesity-associated hypertension and kidney disease.Curr Opin Nephrol Hypertens. 2003 Mar;12(2):195-200. doi: 10.1097/00041552-200303000-00011. Curr Opin Nephrol Hypertens. 2003. PMID: 12589181 Review.
-
Pathophysiology of obesity hypertension.Curr Hypertens Rep. 2000 Apr;2(2):139-47. doi: 10.1007/s11906-000-0073-4. Curr Hypertens Rep. 2000. PMID: 10981140 Review.
Cited by
-
Adipocyte-derived factor reduces vasodilatory capability in ob-/ob- mice.Am J Physiol Heart Circ Physiol. 2009 Aug;297(2):H689-95. doi: 10.1152/ajpheart.01327.2008. Epub 2009 Jun 5. Am J Physiol Heart Circ Physiol. 2009. PMID: 19502550 Free PMC article.
-
The pathophysiology of hypertension in patients with obesity.Nat Rev Endocrinol. 2014 Jun;10(6):364-76. doi: 10.1038/nrendo.2014.44. Epub 2014 Apr 15. Nat Rev Endocrinol. 2014. PMID: 24732974 Free PMC article. Review.
-
Leptinemia and its association with stroke and coronary heart disease in the Jackson Heart Study.Clin Endocrinol (Oxf). 2010 Jan;72(1):32-7. doi: 10.1111/j.1365-2265.2009.03627.x. Epub 2009 May 16. Clin Endocrinol (Oxf). 2010. PMID: 19473179 Free PMC article.
-
Nonpharmacologic therapy for hypertension: does it really work?Curr Cardiol Rep. 2006 Nov;8(6):418-24. doi: 10.1007/s11886-006-0099-6. Curr Cardiol Rep. 2006. PMID: 17059793 Review.
-
The Pivotal Role of Adipocyte-Na K peptide in Reversing Systemic Inflammation in Obesity and COVID-19 in the Development of Heart Failure.Antioxidants (Basel). 2020 Nov 14;9(11):1129. doi: 10.3390/antiox9111129. Antioxidants (Basel). 2020. PMID: 33202598 Free PMC article. Review.